1. Home
  2. IVVD vs CULP Comparison

IVVD vs CULP Comparison

Compare IVVD & CULP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVVD
  • CULP
  • Stock Information
  • Founded
  • IVVD 2020
  • CULP 1972
  • Country
  • IVVD United States
  • CULP United States
  • Employees
  • IVVD N/A
  • CULP N/A
  • Industry
  • IVVD Biotechnology: Pharmaceutical Preparations
  • CULP Textiles
  • Sector
  • IVVD Health Care
  • CULP Consumer Discretionary
  • Exchange
  • IVVD Nasdaq
  • CULP Nasdaq
  • Market Cap
  • IVVD 63.4M
  • CULP 54.5M
  • IPO Year
  • IVVD 2021
  • CULP N/A
  • Fundamental
  • Price
  • IVVD $1.60
  • CULP $4.35
  • Analyst Decision
  • IVVD Strong Buy
  • CULP
  • Analyst Count
  • IVVD 5
  • CULP 0
  • Target Price
  • IVVD $5.11
  • CULP N/A
  • AVG Volume (30 Days)
  • IVVD 4.4M
  • CULP 32.2K
  • Earning Date
  • IVVD 11-13-2025
  • CULP 09-10-2025
  • Dividend Yield
  • IVVD N/A
  • CULP N/A
  • EPS Growth
  • IVVD N/A
  • CULP N/A
  • EPS
  • IVVD N/A
  • CULP N/A
  • Revenue
  • IVVD $46,210,000.00
  • CULP $207,391,000.00
  • Revenue This Year
  • IVVD $112.35
  • CULP $2.41
  • Revenue Next Year
  • IVVD $272.14
  • CULP $3.46
  • P/E Ratio
  • IVVD N/A
  • CULP N/A
  • Revenue Growth
  • IVVD 1941.08
  • CULP N/A
  • 52 Week Low
  • IVVD $0.35
  • CULP $3.42
  • 52 Week High
  • IVVD $2.74
  • CULP $6.22
  • Technical
  • Relative Strength Index (RSI)
  • IVVD 71.86
  • CULP 51.67
  • Support Level
  • IVVD $1.15
  • CULP $4.25
  • Resistance Level
  • IVVD $1.15
  • CULP $4.40
  • Average True Range (ATR)
  • IVVD 0.12
  • CULP 0.17
  • MACD
  • IVVD 0.02
  • CULP -0.00
  • Stochastic Oscillator
  • IVVD 99.85
  • CULP 30.34

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

About CULP Culp Inc.

Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.

Share on Social Networks: